Who are Fludrocortisone/ Fludrocortisone acetate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fludrocortisone Acetate Tablets.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fludrocortisone-fludrocortisone-acetate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Fludrocortisone/ Fludrocortisone acetate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fludrocortisone/ Fludrocortisone acetate (Fludrocortisone/ Fludrocortisone acetate) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mineralocorticoid receptor agonist; corticosteroid. Area: Endocrinology; Cardiovascular.

marketed Mineralocorticoid receptor agonist; corticosteroid Mineralocorticoid receptor (MR) Endocrinology; Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Fludrocortisone/ Fludrocortisone acetate (Fludrocortisone/ Fludrocortisone acetate) — Merck Sharp & Dohme LLC. Fludrocortisone is a synthetic corticosteroid that acts as a mineralocorticoid receptor agonist, increasing sodium reabsorption and potassium excretion in the kidneys to regulate fluid and electrolyte balance.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fludrocortisone/ Fludrocortisone acetate TARGET	Fludrocortisone/ Fludrocortisone acetate	Merck Sharp & Dohme LLC	marketed	Mineralocorticoid receptor agonist; corticosteroid	Mineralocorticoid receptor (MR)
Fludrocortisone Acetate Tablets	Fludrocortisone Acetate Tablets	Tehran Heart Center	phase 3	Mineralocorticoid receptor agonist	Mineralocorticoid receptor (MR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mineralocorticoid receptor agonist; corticosteroid class)

Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fludrocortisone/ Fludrocortisone acetate — Competitive Intelligence Brief. https://druglandscape.com/ci/fludrocortisone-fludrocortisone-acetate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab